A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma.

KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA), but remains an intractable pharmacological target. Consequently, defining RAS effector pathway(s) required for PDA initiation and maintenance is critical to improve treatment of this disease. Here we demonstrate that expression o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Collisson, Eric A., Trejo, Christy, Silva, Jillian, Gu, Shenda, Korkola, James E., Heiser, Laura, Charles, Roch-Philippe, Rabinovich, Brian A., Hann, Byron, Dankort, David, Spellman, Paul T., Phillips, Wayne, Gray, Joe W., McMahon, Martin
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425446/
https://ncbi.nlm.nih.gov/pubmed/22628411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0347
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares